Mayne Pharma Group (Acquired 2009) Overview
- Founded
-
2005
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
Mayne Pharma Group (Acquired 2009) General Information
Description
Developer of pharmaceutical drugs and formulations. The company's pharmaceutical drugs and formulations include a variety of oral medicines in the form of capsules as well as tropical and surgical medicines, enabling pharmaceuticals, physicians and patients to get quality pharmaceutical products. Mayne Pharma Group was the developer of pharmaceutical drugs and formulations. The company's pharmaceutical drugs and formulations included a variety of oral medicines in the form of capsules as well as tropical and surgical medicines, enabling pharmaceuticals, physicians and patients to get quality pharmaceutical products. It was founded in November 2005 and was headquartered in Salisbury, Australia. The company, a subsidiary of Hospira, was acquired by Halcygen Pharmaceuticals (ASX: HGN) for an undisclosed amount in October 2009.
Contact Information
- Salisbury, South Australia
- Australia
Mayne Pharma Group (Acquired 2009) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mayne Pharma Group (Acquired 2009) Patents
Mayne Pharma Group (Acquired 2009) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019277362-A1 | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome | Pending | 30-May-2018 | 0000000000 | |
| EP-3814349-A1 | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome | Inactive | 30-May-2018 | 0000000000 | |
| EP-3814349-A4 | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome | Inactive | 30-May-2018 | 0000000000 | 0 |
| US-20190365743-A1 | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome | Inactive | 30-May-2018 | 0000000000 | |
| US-20160263129-A1 | Controlled release doxycycline | Inactive | 08-Oct-2014 | A61K31/65 | 0 |
Mayne Pharma Group (Acquired 2009) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|